35 results about "Mental nerve" patented technology

The invention relates to compositions for supporting healthy memory and optimizing mental energy and methods for improving, preventing, and treating mental disorders or deterioration. The compositions of the invention can be formulated as nutritional or dietary supplements.

Devices and methods are disclosed that allow a patient to self-treat a medical condition, such as migraine headache and trigeminal neuralgia and the like, by noninvasive electrical stimulation of nerves of the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the vicinity of their foramen or notch. The system comprises a handheld mobile device, such as a smartphone, that is applied to the surface of the patient's head. One or more electrodes on the mobile device apply electrical impulses transcutaneously through the patient's skin to the targeted nerve to treat the medical condition. The system is designed to address problems that arise particularly during self-treatment, when a medical professional is not present.

A compound represented by general formula (I):

a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than ½. The methods of the present invention may be used to address a whole host of undesirable mental, neurological and physiological conditions.

The present invention relates to a preventive and/or therapeutic agent for psychoneurotic diseases, comprising an EP₃ antagonist represented by the general formula (I):

(wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP₃ and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.

A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

A therapeutic drug for psychoneurotic disorders, which is useful for therapies of psychoneurotic disorders, especially restless legs syndrome is disclosed. The therapeutic drug for psychoneurotic disorders according to the present invention comprises as an effective ingredient an opioid κ receptor agonist compound (excluding pentazocine) such as (−)-17-(cyclopropylmethyl)-3,14β-dihydroxy-4,5α-epoxy-6β[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloric acid salt.

A mentation test method that can test mentation of a human such as conjecture of brain's mentation age, discrimination of early stage of dementia and prediction of onset of dementia in addition to diagnosis of prediction probability of onset of dementia and screening of mental functions of senile dementia patients, decision of the effect of rehabilitation of the aftereffects of cerebrovascular disfunction, investigation of the therapeutic effects of medicines and side effects such as sleepiness, testing of degree of intoxication, testing of peripheral attention visual field, testing of cerebral dominant hemisphere, testing of various psychoneurosis such as schizophrenia and cerebrovascular disorder (syndrome and diagnosis, and decision of the effects of rehabilitation and treatment), and check of the degree of fatigue.

A compound represented by general formula (I):

a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

The invention relates to a composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia, belongs to the field of medicine health, and provides a composition capable of alleviating asthenopia. The active components of the composition comprise fish eyeball tissues or an extract thereof, fish eye socket tissues and an extract thereof, the theanine and the gamma-aminobutyric acid. Test results in crowds prove that the composition has effect on eye local symptoms of asthenopia, can obviously improve the neurosis symptoms caused by asthenopia of different degrees, such as unconcentrated attention, and reduced memory, is notable in effect of alleviating asthenopia and has broad market development prospect.

The present invention relates to a compound represented by formula (I):

wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof.

The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

The invention relates to a composition containing fish eyes, theanine and phosphatidylserine for relieving visual fatigue, and belongs to the field of medicines and health. The invention provides a composition for relieving visual fatigue. The active ingredients of the composition comprise fish eyeball tissue or an extract thereof, fish eye socket tissue or an extract thereof, theanine and phosphatidylserine. The trial results of crowds show that the composition disclosed by the invention not only aims at the local symptoms of eyes having visual fatigue, but also can significantly improve neuropsychological syndromes caused by different degrees of visual fatigue, such as inattention, memory deterioration, and the composition is notable in the effect of relieving the visual fatigue, and hasbroad market prospects.

Soymilk is provided which can prevent or alleviate menopausal disorders, and is highly safe with no risk of side effects even with long-term intake thereof. This soymilk is made from germinated soybeans, and is used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms associated with menopausal disorders. Furthermore, this soymilk is labeled with a notice specifying that the soymilk is to be used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms of menopausal disorders.

The invention relates to a theanine, [gamma]-aminobutyric acid and anthocyanin containing composition for relieving visual fatigue, and belongs to the field of medical health. According to the composition for relieving the visual fatigue provided by the invention, active ingredients include theanine, [gamma]-aminobutyric acid and anthocyanin. Based upon trial results on people, it is indicated that the composition not only can relieve local symptoms of eyes having the visual fatigue but also can obviously improve psychoneural symptoms, such as attention-deficit disorder, memory loss and the like, caused by visual fatigue of different degrees; and the composition is obvious in effect of relieving the visual fatigue and has a broad market prospect.

Belonging to the field of medical health, the invention relates to a visual fatigue-alleviating composition containing Chinese wolfberry, chrysanthemum, gamma-aminobutyric acid and theanine. The invention provides the visual fatigue-alleviating composition, and the active ingredients include Chinese wolfberry, chrysanthemum, gamma-aminobutyric acid and theanine. The population trial result indicates that the composition provided by the invention is not only directed at the local symptoms of visual fatigue eyes, but also can obviously improve the neuropsychiatric symptoms caused by different degrees of visual fatigue, like inattention, memory deterioration and the like, has significant visual fatigue-alleviating effect, and has broad market prospects.

The invention relates to application of theanine in preparing food, health products or medicines for relieving eye fatigue, and belongs to the field of medicine and health. One of the technical schemes of the invention provides the application of the theanine in preparing the food, health products or medicines for relieving eye fatigue. In addition, the invention also provides a composition for relieving eye fatigue, and the active components of the composition comprise theanine and anthocyanin. Shown by trial results of people, the composition provided by the invention aims at local symptomsof eye fatigue, can obviously improve psychosomatic manifestations such as aprosexia and memory decline caused by varying degrees of eye fatigue, has an obvious effect of relieving eye fatigue and hasbroad market prospects.

The invention relates to a composition containing fructus lycii, flos chrysanthemi, phosphatidylserine and theanine for relieving visual fatigue, and belongs to the field of medicine and health. The invention provides the composition for relieving visual fatigue, which is prepared from the active ingredients: the fructus lycii, the flos chrysanthemi, the phosphatidylserine and the theanine. The test result shows that the composition provided by the invention not only aims at visual fatigue eye local symptoms but also can remarkably improve psychosomatic manifestations such as inattention and memory deterioration caused by different degrees of visual fatigue, the composition has a remarkable effect on relieving visual fatigue, and has a broad market prospect.

The invention discloses a traditional Chinese medicine preparation for treating climacteric syndrome of women. The preparation is prepared from raw materials and auxiliary materials. The raw materials comprise the following components in parts by weight: 31-40 parts of cibotium barometz, 25-35 parts of salvia miltiorrhiza, 18-24 parts of curcuma zedoary, 18-24 parts of trifid sopubia herb, 15-25 parts of telegraph plants, 25-33 parts of habenaria dentate, 32-46 parts of fried spina date seed and 12-20 parts of angelica sinensis. The traditional Chinese medicine preparation disclosed by the invention can effectively improve the level of estradiol of women with climacteric syndrome and alleviate vasomotor symptom, autonomic imbalance and psychosomatic manifestations.

The invention discloses application of resveratrol to preparing medicines for treating sub-clinical hypothyroidism and neuropsychiatric syndromes due to the sub-clinical hypothyroidism. The application has the advantages that the resveratrol is applied to preparing the medicines for treating the sub-clinical hypothyroidism and the neuropsychiatric syndromes due to the sub-clinical hypothyroidism, accordingly, imbalance hypothalamus-pituitary-thyroid axis functions of sub-clinical hypothyroidism patients can be improved, the learning and memory ability of the sub-clinical hypothyroidism patients can be enhanced, and depression-related behavior of the sub-clinical hypothyroidism can be improved.